throbber
2/3/2022
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`FILTER NEWS
`
`▶ All (704,885)
`
`▶ Topic (671,028)
`
`▶ Industry (116,706)
`
`▶ Hotbed/Location
`(649,062)
`
`▶ Career Advice
`(3,629)
`
`▶ Employer Insights
`(84)
`
`▶ Therapeutic
`Insights (514)
`
`▶ Coronavirus
`(COVID-19) News
`
`(1,965)
`
`Genentech, Inc.
`Submits Biologics
`License Application For
`FDA Review Of
`Lucentis(TM) In Wet
`Age-Related Macular
`Degeneration
`
`Published: Dec 30, 2005
`
`SOUTH SAN FRANCISCO, Calif., Dec. 30
`/PRNewswire-FirstCall/ -- Genentech, Inc.
`announced today that it has submitted a
`Biologics License Application (BLA) to the U.S.
`Food and Drug Administration (FDA) for the
`use of Lucentis(TM) (ranibizumab) in the
`treatment of neovascular wet age-related
`macular degeneration (AMD). Lucentis is the
`first therapy for wet AMD to have shown
`improved vision in two pivotal Phase III trials
`and demonstrated a clinical benefit over
`verteporfin (Visudyne(R)) photodynamic
`therapy (PDT) in a head-to-head clinical trial. As
`part of the Lucentis BLA submission,
`Genentech has requested a Priority Review
`designation from the FDA, which, if granted,
`would give the FDA six months from the
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 1/11
`
`Exhibit 2120
`Page 01 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`Agency's receipt of the submission to take
`action on the application.
`
`The BLA submission is based on one-year
`clinical data on the efficacy and safety of
`Lucentis from two pivotal Phase III trials,
`ANCHOR and MARINA, as well as one-year
`clinical data from the Phase I/II FOCUS trial. In
`addition to these registrational studies,
`Genentech is currently enrolling patients with
`wet AMD in a Phase IIIb safety study called
`SAILOR. Data from the Phase IIIb PIER study
`evaluating a less frequent dosing regimen for
`Lucentis are anticipated in the first half of
`2006.
`
`"This application represents a summary of data
`from more than six years of rigorous clinical
`study and the dedication of thousands of
`patients and physicians hoping to improve
`outcomes for those with this devastating
`disease," said Hal Barron, M.D., Genentech's
`senior vice president of Development and chief
`medical officer. "We look forward to working
`with the FDA in our efforts to bring this
`potential therapy to patients quickly as it may
`offer benefit to patients with all types of wet
`AMD."
`
`ANCHOR
`
`In November 2005, Genentech announced
`positive preliminary data from the pivotal
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 2/11
`
`Exhibit 2120
`Page 02 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`Phase III ANCHOR study (ANti-VEGF Antibody
`for the Treatment of Predominantly Classic
`CHORoidal Neovascularization in AMD), a
`randomized, two-year, multi-center, double-
`masked, active-treatment controlled study
`comparing two different doses of Lucentis to
`PDT in 423 patients with predominantly classic
`wet AMD. Approximately 94 percent of patients
`treated with 0.3 mg of Lucentis and 96 percent
`of those treated with 0.5 mg of Lucentis
`maintained (defined as a loss of less than 15
`letters in visual acuity) or improved vision
`(defined as a gain of 15 letters or more)
`compared to approximately 64 percent of
`those treated with PDT alone [p<0.0001]
`during the first year of the two-year study. The
`Lucentis treatment groups further showed a
`statistically significant difference from the
`control arm in an important secondary
`endpoint: mean change in visual acuity (VA)
`from baseline to month 12. On average, VA
`among patients treated with Lucentis
`improved, while VA among patients treated
`with PDT declined. Based on these results,
`patients in the PDT-alone arm of the study will
`have access to Lucentis for the remainder of
`the study. One-year data from the ANCHOR
`study will be presented at the Macula 2006
`meeting in New York in January.
`
`MARINA
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 3/11
`
`Exhibit 2120
`Page 03 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`In July 2005, Genentech presented positive
`preliminary one-year results from the pivotal
`Phase III MARINA study (Minimally
`classic/occult trial of the Anti-VEGF antibody
`Ranibizumab In the treatment of Neovascular
`AMD), a randomized, two-year, multi-center,
`double-masked, sham-injection controlled
`study evaluating the safety and efficacy of two
`different doses of Lucentis in 716 patients with
`minimally classic or occult wet AMD. Nearly 95
`percent of patients treated with Lucentis
`maintained or improved vision at 12 months.
`Additional one-year results include:
`
`-- Twenty five percent (59/238) of patients
`treated with 0.3 mg of Lucentis and 34 percent
`(81/240) treated with 0.5 mg of Lucentis
`improved vision by a gain of 15 letters or more
`compared to approximately 5 percent (11/238)
`of patients in the control group as measured
`by the ETDRS eye chart. -- Nearly 40 percent
`(188/478) of Lucentis-treated patients (38.7
`percent in the 0.3 mg group and 40 percent in
`the 0.5 mg group) achieved a visual acuity
`score of 20/40 or better compared to 11
`percent (26/238) in the control group. --
`Patients treated with Lucentis gained an
`average of approximately seven letters in visual
`acuity (6.5 letters in the 0.3 mg group and 7.2
`letters in the 0.5 mg group) compared to study
`entry, while those in the control group lost an
`average of 10.5 letters. -- The majority of
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 4/11
`
`Exhibit 2120
`Page 04 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`patients treated with Lucentis (349/478) (74.8
`percent in the 0.3 mg group and 71.3 percent
`in the 0.5 mg group) experienced a letter
`improvement of zero or more compared to
`28.6 percent (68/238) in the sham group.
`
`In October 2005, Genentech announced that
`patients still in the sham arm of the MARINA
`study would be crossed over to active
`treatment with Lucentis.
`
`FOCUS
`
`The FOCUS trial (RhuFab V2 Ocular Treatment
`Combining the Use of Visudyne(R) to Evaluate
`Safety) is a randomized, two-year, multi-center,
`single-masked study evaluating the safety,
`tolerability and efficacy of Lucentis in
`combination with PDT compared to PDT alone
`in 162 patients with predominantly classic
`subfoveal wet AMD. Preliminary one-year data
`were presented in July 2005 and showed that
`approximately 90 percent of patients
`maintained or improved vision when treated
`with the combination of Lucentis and PDT
`compared to approximately 68 percent of
`those treated with PDT alone (p = 0.0003).
`
`Lucentis Safety Profile
`
`In clinical trials to date, the most common side
`effects that occurred more frequently in the
`Lucentis arms (0.3 mg and 0.5 mg) than in the
`control arms were mild to moderate and
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 5/11
`
`Exhibit 2120
`Page 05 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`included: conjunctival hemorrhage, eye pain,
`increased intraocular pressure and vitreous
`floaters.
`
`Serious ocular adverse events that occurred
`more frequently in the Lucentis-treated arms
`were uncommon and included
`endophthalmitis and intraocular inflammation
`(less than 1 percent for each). Among non-
`ocular serious adverse events, cerebral
`vascular events and myocardial infarctions
`were observed in all three arms of both the
`Phase III MARINA and ANCHOR studies; in each
`study the combined rate of these events was
`similar in the control and the 0.3 mg Lucentis
`arms and slightly higher in the 0.5 mg Lucentis
`arm. Cerebral vascular events and myocardial
`infarctions were also seen in the Phase I/II
`study of Lucentis 0.5 mg in combination with
`Visudyne PDT (FOCUS), although the combined
`frequency of these events was approximately
`equal in both treatment arms.
`
`Additional Phase III Studies
`
`SAILOR
`
`In November 2005, Genentech began
`enrollment in a Phase IIIb study, SAILOR, to
`make Lucentis available to eligible patients.
`SAILOR (Safety Assessment of Intravitreal
`Lucentis fOR AMD) is a Phase IIIb clinical study
`of Lucentis for patients with all types of new or
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 6/11
`
`Exhibit 2120
`Page 06 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`recurrent active subfoveal wet AMD. It is a one-
`year study designed to evaluate the safety of
`two different doses (0.3 mg and 0.5 mg) of
`Lucentis administered once a month for three
`months and thereafter as needed based on
`retreatment criteria. The study will be
`conducted at more than 100 sites in the
`United States and will enroll up to 5,000
`patients. Those interested in additional
`information about the study can call toll-free 1-
`888-662-6728.
`
`PIER
`
`Genentech is also conducting PIER (A Phase
`IIIb, Multi-center, Randomized, Double-Masked,
`Sham Injection-Controlled Study of the Efficacy
`and Safety of Ranibizumab in Subjects with
`Subfoveal Choroidal Neovascularization with or
`without Classic CNV Secondary to Age-Related
`Macular Degeneration) with 184 patients in the
`United States. In this trial, Lucentis is
`administered once per month for the first
`three months followed thereafter by doses
`once every three months for a total of 24
`months. Enrollment in this study is complete
`and preliminary results are expected in the
`first half of 2006.
`
`About AMD
`
`AMD is a major cause of painless central visual
`loss and is the leading cause of blindness for
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 7/11
`
`Exhibit 2120
`Page 07 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`people over the age of 60. The National Eye
`Institute estimates that there are 1.6 million
`people with AMD in the United States alone
`and that this prevalence will grow to 2.95
`million by 2020. AMD occurs in two forms: dry
`and wet.
`
`The dry form is associated with atrophic cell
`death of the central retina or macula, which is
`required for fine vision used for activities such
`as reading, driving or recognizing faces. The
`wet form is caused by growth of abnormal
`blood vessels also known as choroidal
`neovascularization (CNV) or ocular
`angiogenesis under the macula. These vessels
`leak fluid and blood and cause scar tissue that
`destroys the central retina. This results in a
`deterioration of sight over a period of months
`to years.
`
`About Lucentis
`
`Lucentis(TM) (ranibizumab) is a humanized
`therapeutic antibody fragment developed at
`Genentech and designed to bind and inhibit
`VEGF-A, a protein that is believed to play a
`critical role in angiogenesis (the formation of
`new blood vessels). Lucentis is designed to
`block new blood vessel growth and leakiness,
`which lead to wet AMD disease progression
`and vision loss.
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 8/11
`
`Exhibit 2120
`Page 08 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`Lucentis is being developed by Genentech and
`the Novartis Ophthalmics Business Unit.
`Genentech retains commercial rights for
`Lucentis in North America. Novartis has
`exclusive commercialization rights for the rest
`of the world.
`
`About Angiogenesis
`
`Genentech is a leader in research and product
`development in the area of angiogenesis, the
`process by which new blood vessels are
`formed. In 1989 Napoleone Ferrara, M.D., and
`a team of scientists at Genentech conducted
`seminal work in the field, which resulted in the
`identification and cloning of a gene termed
`Vascular Endothelial Growth Factor (VEGF),
`now known as VEGF-A. The VEGF-A protein is
`believed to play a critical role in angiogenesis
`and serves as one of the key contributors to
`physiological or pathological conditions that
`can stimulate the formation of new blood
`vessels. The process of angiogenesis is
`normally regulated throughout development
`and adult life, and the uncontrolled growth of
`new blood vessels is an important contributor
`to a number of pathologic conditions, including
`wet AMD.
`
`About Genentech
`
`Genentech is a leading biotechnology
`company that discovers, develops,
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-macul… 9/11
`
`Exhibit 2120
`Page 09 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`manufactures and commercializes
`biotherapeutics for significant unmet medical
`needs. A considerable number of the currently
`approved biotechnology products originated
`from, or are based on, Genentech science.
`Genentech manufactures and commercializes
`multiple biotechnology products directly in the
`United States and licenses several additional
`products to other companies. The company
`has headquarters in South San Francisco,
`Calif., and is traded on the New York Stock
`Exchange under the symbol DNA. For
`additional information about the company,
`http://www.gene.com
`please visit
` .
`
`This press release contains forward-looking
`statements regarding Lucentis as a potential
`therapy and the expected time frame for the
`PIER trial results. Actual results could differ
`materially. Among other things, the time frame
`for the PIER results could be affected by
`unexpected safety or efficacy issues, additional
`time requirements to achieve study endpoints
`or for data analysis, or discussions with the
`FDA or FDA actions; and Lucentis as a potential
`therapy could be affected by certain of the
`forgoing and the failure to receive FDA
`approval, competition, pricing and the ability to
`supply product or a product withdrawal.
`Genentech disclaims any obligation and does
`not undertake to update or revise the forward-
`looking statements in this press release.
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-mac… 10/11
`
`Exhibit 2120
`Page 10 of 11
`
`

`

`2/3/2022
`
`Genentech, Inc. Submits Biologics License Application For FDA Review Of Lucentis(TM) In Wet Age-Related Macular Degeneration | BioS…
`Media Contact: Dawn Kalmar 650-225-5873
`
`Investor Contact: Kathee Littrell 650-225-1034
`
`Patient Inquiries: 1-888-662-6728
`
`Genentech, Inc.
`CONTACT: media, Dawn Kalmar, +1-650-225-
`5873, or investors, KatheeLittrell, +1-650-225-
`1034, or patients, 1-888-662-6728, all of
`Genentech
`
`Web site: http://www.gene.com/
`
`Related links
`
`Reuters
`
`
`
`
`
`
`✉ F T L 𝓟 r
`
`◄ Back to news
`
`https://www.biospace.com/article/releases/genentech-inc-submits-biologics-license-application-for-fda-review-of-lucentis-tm-in-wet-age-related-mac… 11/11
`
`Exhibit 2120
`Page 11 of 11
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket